• 1
    Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002;15:172186.
  • 2
    Hayden MR, Tyagi SC, Kolb LG, et al. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol [serial online]. 2005;4:4.
  • 3
    Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61:22102217.
  • 4
    Angelis M, Wong LL, Myers SA. et al. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122:10831089.
  • 5
    Yatzidis H, Agroyannis B. Sodium thiosulfate treatment of soft-tissue calcifications in patients with end-stage renal disease. Peritoneal Dial Bull. 1987;7:250252.
  • 6
    Kyriakopoulos G, Kontogianni K. Sodium thiosulfate treatment of tumoral calcinosis in patients with end-stage renal disease. Ren Fail. 1990;12:213219.
  • 7
    Papadakis JT, Patrikarea A, Digenis GE, et al. Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism. Nephron. 1996;72:308312.
  • 8
    Cicone JS, Petronis JB, Embert CD. et al. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004;43:11041108.
  • 9
    Don BR, Chin AI. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol. 2003;59:463470.